0001209191-22-006796.txt : 20220203 0001209191-22-006796.hdr.sgml : 20220203 20220203162928 ACCESSION NUMBER: 0001209191-22-006796 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20220201 FILED AS OF DATE: 20220203 DATE AS OF CHANGE: 20220203 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: WAGNER CHARLES F JR CENTRAL INDEX KEY: 0001223348 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 22588760 MAIL ADDRESS: STREET 1: C/O MILLIPORE CORP CITY: BILLERICA STATE: MA ZIP: 01820 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-02-01 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001223348 WAGNER CHARLES F JR C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 0 1 0 0 EVP & Chief Financial Officer Common Stock 2022-02-01 4 A 0 3698 0.00 A 38489 D Common Stock 2022-02-01 4 A 0 11628 0.00 A 50117 D Common Stock 2022-02-01 4 A 0 10262 0.00 A 60379 D Common Stock 2022-02-02 4 S 0 2944 250.07 D 57435 D Represents earned performance shares with respect to a performance stock unit award granted on 04/10/2019 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest on 02/24/2022. Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest in installments beginning on 02/17/2022. Restricted stock unit award that vests in installments beginning on 02/24/2023. Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. Open market sales reported on this line occurred at a weighted average price of $250.07 (range $250.00 to $250.09). Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Exhibit 24 - Power of Attorney /s/ Sabrina Yohai, Attorney-in-Fact 2022-02-03 EX-24 2 attachment1.htm EX-24 DOCUMENT

POWER OF ATTORNEY
	The undersigned hereby constitutes and appoints each of Joy Liu, Sabrina Yohai,
Omar White, and Christiana Stevenson of Vertex Pharmaceuticals Incorporated (the
"Company"), signing singly, with full power of substitution, the undersigned's
true and lawful attorney-in-fact to:
1. execute for and on behalf of the undersigned, in the undersigned's capacity
as an officer, director and/or 10% shareholder of the Company, forms and
authentication documents for EDGAR Filing Access;

2. do and perform any and all acts for and on behalf of the undersigned which
may be necessary or desirable to complete and execute any such forms and
authentication documents;

3. execute for and on behalf of the undersigned, in the undersigned's capacity
as an officer, director and/or 10% shareholder of the Company, Forms 3, 4 and 5
in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the
rules thereunder;

4. do and perform any and all acts for and on behalf of the undersigned which
may be necessary or desirable to complete and execute any such Form 3, 4 or 5
and timely file such form with the United States Securities and Exchange
Commission and any stock exchange or similar authority; and

5. take any other action of any type whatsoever in connection with the foregoing
which, in the opinion of such attorney-in-fact, may be of benefit to, in the
best interests of, or legally required by the undersigned, it being understood
that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in fact's discretion.
The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted.  The undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the undersigned, are not assuming,
nor is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Securities Exchange Act of 1934, as amended.
This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 with respect to the
undersigned's holdings of or transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.
This Power of Attorney is intended to constitute a "confirming statement" for
presentation to the Securities and Exchange Commission as contemplated by
Instruction 7(a) of Forms 3, 4 and 5.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed this 17th day of January, 2022.

/s/ Charles F. Wagner, Jr.
Signature

Charles F. Wagner, Jr.
Print Name